Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Leukemia inhibitory factor (LIF) suppresses the differentiation of myoblasts, and inhibits the activation of caspase-3 and blocks the reduction in Bcl-xL (B-cell lymphoma-extra large) levels, thus, preventing doxorubicin-induced apoptosis. Along with transforming growth factor β2 (TGFβ2)/fibroblast growth factor 2 (FGF2), LIF regulates nephrogenesis. It facilitates tubular regeneration following acute kidney failure. It plays a crucial role in neuroprotective pathways induced by preconditioning-induced oxidative stress. LIF is capable of maintaining the totipotency of embryonic stem cells. It is also involved in controlling the differentiation of embryonic stem cells, hematopoietic and neuronal cells.

General description

Leukemia inhibitory factor (LIF) is a secreted pleiotropic glycoprotein which is a member of the gp130 signaling of interleukin-6 (IL-6) family cytokines. This protein was originally identified as a protein that prevented the growth of a leukemic cell line. Recombinant human LIF is a 19.6 kDa protein containing 180 amino acids residues including three disulfide bonds.

Physical form

Lyophilized with no additives

Reconstitution

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.